Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29722743 | 1.00 | MPO (0.50) | MPOHSD17B10PDK1PDK2PDK3 | |
| SCHEMBL29088763 | 0.91 | HSD17B10 (0.49) | MPOHSD17B10PDK1PDK2PDK3 | |
| SCHEMBL22075927 | 0.89 | ALDH1A1 (0.48) | HSD17B10PDK1PDK2PDK3PDK4 | |
| SCHEMBL30369865 | 0.88 | MAPT (0.48) | HSD17B10PDK1PDK2PDK3PDK4 | |
| SCHEMBL22075960 | 0.88 | MAPT (0.48) | HSD17B10PDK1PDK2PDK3PDK4 | |
| SCHEMBL3657122 | 0.85 | HSD17B10 (0.48) | MPOHSD17B10PDK1PDK2PDK3 | |
| SCHEMBL25316782 | 0.85 | HSD17B10 (0.48) | MPOHSD17B10PDK1PDK2PDK3 | |
| SCHEMBL3656194 | 0.84 | HSD17B10 (0.50) | MPOHSD17B10PDK1PDK2PDK3 | |
| SCHEMBL5639016 | 0.84 | HSD17B10 (0.46) | MPOHSD17B10PDK1PDK2PDK3 | |
| SCHEMBL5637860 | 0.83 | HSD17B10 (0.46) | MPOHSD17B10PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | PSMG3, MYCBP2, PSME2 | MPO 3648/4885HSD17B10 3039/4885PDK1 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.